Table 3.
Clinical outcomes
| Variables | No-Anticoagulation Group | Regional Citrate Anticoagulation Group | Difference between Groups (95% CI) | P Value |
|---|---|---|---|---|
| Primary outcome, n (%) | ||||
| Filter failure | 25 (56) | 12 (27) | — | 0.007 |
| Filter failurea | 16 (57) | 9 (30) | — | 0.04 |
| Secondary outcomes, n (%) | ||||
| Other reasons for circuit termination | ||||
| Completed 72 h of filter useb | 1 (2) | 14 (32) | — | |
| Termination of CKRTc | 12 (27) | 13 (30) | — | |
| Patient death | 6 (13) | 4 (9) | — | |
| Transportd | 1 (2) | 1 (2) | — | |
| Actual filter duration, h, mean (SD) | 28 (19) | 44 (23) | 16 (7 to 25) | 0.001 |
| Bleeding, n (%)e | 2 (4) | 0 (0) | — | 0.49 |
| RBC transfusion, n (%) | 6 (13) | 1 (2) | — | 0.11 |
| RBC transfusion volume, ml, median (IQR) | 400 (291–1811) | 900 (900–900) | — | 0.86 |
| Plasma transfusion, n (%) | 13 (29) | 8 (18) | — | 0.23 |
| Plasma transfusion volume, ml, median (IQR) | 400 (330–930) | 410 (238–910) | — | 0.97 |
| Other outcomes | ||||
| Vasopressor initiation after randomization, n (%)f | 2 (4) | 2 (5) | — | 1.00 |
| Increased vasopressor dose after randomization, n (%)g | 3 (7) | 2 (5) | — | 1.00 |
| ICU time, d, median (IQR) | 9 (5–18) | 10 (7–20) | — | 0.52 |
| In-hospital time, d, median (IQR) | 16 (9–23) | 14 (9–21) | — | 1.00 |
| 28-d mortality, n (%) | 22 (49) | 23 (52) | — | 0.75 |
CI, confidence interval; CKRT, continuous KRT; ICU, intensive care unit; IQR, interquartile range; RBC, red blood cell.
a
Sensitivity analysis included only the first filter of continuous KRT.
b
The upper filter use time limitation of manufacturer's recommendation was 72 hours.
c
Achievement of treatment goal.
d
Transport for outward examination or interventional procedure.
e
Major bleeding required red blood cell transfusion and/or operation/reoperation.
f
Newly prescribed vasopressors during the observed continuous KRT session.
g
Increased vasopressor dose during the observed continuous KRT session.